Digital Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

The Digital Therapeutics market is expected to grow at a steady CAGR forecast till 2030 owing to the increasing accessibility of virtual care and shifting focus among the population on lowering healthcare costs.

Thedigital therapeutics market is estimated to grow at a CAGR of 27.73% during the forecast period from 2024 to 2030. The demand for digital therapeutics is being boosted by the increasing prevalence of chronic diseases such as diabetes, mental illness, cancer, and heart failure (HF), advancements in technology such as in mobile technology, wearable devices, artificial intelligence, machine learning, and data analytics, regulatory support, insurance coverage, strategic partnerships and investments, among others are some of the major factors contributing to the overall growth of the digital therapeutics market during the forecast period from 2024 to 2030.

Digital Therapeutics Market Dynamics:

As per the International Diabetes Federation (2022), in 2021, approximately 537 million people were living with diabetes globally. As per the same source, the total number of patients suffering from diabetes is projected to grow to about 643 million patients by the year 2030 and about 783 million people by 2045.

Digital therapeutic applications (DTx) such as Blue Star, Diabeo System, Livongo Diabetes Program, and Tidepool, among others, use web-based applications or cloud platforms to provide an evidence-based, personalized, rapid point-of-care management of chronic, behavior-modifiable conditions, including diabetes mellitus. DTx can improve patient compliance, therapeutic success, and economic outcomes in diabetes management by enabling active patient engagement, lifestyle change, comprehensive medical care, and periodic monitoring of glycemic status. Thus, the rising prevalence of diabetes will increase the demand for digital therapeutic software which are used in the management and treatment of diabetes, thereby propelling the overall market of digital therapeutics.

The market is anticipated to be driven by the rising smartphone adoption in both developed and developing nations, the affordability of digital health technology for patients and providers, and rising demand for patient-centered care and integrated healthcare systems. Kepios stated that 4.27 billion people used the internet worldwide in April 2021, making up more than 60% of the world's population. It is anticipated that this number is expected to increase, so will public awareness of smart health tracking in the upcoming years.

The increasing focus of major key players on developing technologically advanced software with easy access for physicians and patients is expected to propel the market during the forecast period. For instance, in July 2022, AmerisourceBergen Corporation launched DTx Connect, a fully integrated ordering, dispensing, and fulfillment platform that aims to facilitate patient access to physician-ordered therapeutics and diagnostics. The platform integrates with electronic medical records (EMR), giving physicians easy access to prescription and non-prescription therapies.

Therefore, all the above-mentioned factors are contributing to the growth of the digital therapeutics market during the forecast period from 2024 to 2030.

However, cybersecurity and privacy concerns, and unstable payment models, among others may restrict the digital therapeutics market growth in the upcoming years.

Digital Therapeutics Market Segment Analysis:

Digital Therapeutics market by Product (Prevention, Management, and Treatment), Indication (Diabetes, Obesity, Cardiovascular Diseases, Respiratory Diseases, and Others), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World)

In the indication segment of the digital therapeutics market, the obesity category is expected to amass a significant revenue share in the year 2023. This can be attributed to the increasing patient population associated with obesity across the globe.

The World Obesity Atlas 2022, published by the World Obesity Federation, predicted that one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030. Obesity is a major public health challenge that affects almost every country in the world. Globally, obesity rates have been increasing steadily over the last three decades. In almost every region, there are now more people living with obesity than underweight, and if current numbers continue to rise, as many as 1 billion adults, or 12% of the world population, will be living with obesity by 2025. The above-mentioned source also stated that almost 2.3 billion children and adults were living with overweight and obesity, in 2022, globally and if current trends continue, 2.7 billion adults could be living with overweight or obesity by 2025.

The World Health Organization (WHO) European Regional Obesity Report 2022, stated that overweight and obesity affect almost 60% of adults and nearly one in three children (29% of boys and 27% of girls) in the WHO European Region, in 2022.

The use of a digital therapeutics platform in people with obesity and metabolic syndrome can lead to a reduction in both weight and body mass index (BMI), thereby reducing the risk for comorbidities. Digital therapeutic platforms allow clinicians to deliver lifestyle-modification interventions remotely. These interventions have the potential to influence weight loss in people with obesity and metabolic syndrome through the delivery of evidence-based care even in settings that are resource-limited. Thus, the increasing prevalence of obesity and overweight will increase the demand for digital therapeutics for managing and treating obesity and overweight.

Additionally, the WDTx Platform by Wellthy Therapeutics Pvt Ltd. provides a 52-week lifestyle modification program focused on diet, physical activity, weight management, remote patient monitoring, glycemic control, and blood pressure control. The platform provides artificial intelligence-augmented healthcare tracking, evidence-backed content, and personalized health coach support.

Thus, all the above-mentioned factors are likely to propel the demand for obesity-managing digital therapeutics, thereby contributing to the growth of the digital therapeutics market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall digital therapeutics market:

North America is expected to account for the highest proportion of the Digital Therapeutics market in 2023, out of all regions. This domination is due to the increasing demand for digital therapeutics among the physicians and patients in the region, the increasing patient pool suffering from chronic diseases, the rising demand for remote patient monitoring and telemedicine, the presence of key market players, among factors contributing to the growth of the digital therapeutics market in North America.

According to Administration for Community Living, an operating division of the U.S. Department of Health and Human Services (2024) stated that in the year 2022, individuals aged 65 and older comprised 17.3% of the population. This percentage is projected to increase to 22% by the year 2040.

Thus rising burden of the geriatric population in the region will increase the demand for digital therapeutics as elderly patients are more prone to chronic diseases including major depressive disorder (MDD), which can significantly impair their quality of life. Digital therapeutics offer a viable solution by providing accessible, scalable, and cost-effective tools that can be used alongside traditional treatments.

The favorable regulatory approvals by the authorities will propel the overall market for digital therapeutics in the region. For instance, in April 2024, the U.S. Food and Drug Administration (FDA) granted marketing clearance to Otsuka America Pharmaceutical, Inc. for Rejoyn, a prescription digital therapeutic smartphone application. The app is designed for the treatment of Major Depressive Disorder (MDD) as an adjunct to clinician-managed outpatient care for adult patients aged 22 years and older who are currently on antidepressant medication.

Furthermore, the growing healthcare IT expenditure to advance infrastructure, technological literacy, readiness to adopt advanced technological solutions, favorable government initiatives, the emergence of startups, lucrative funding options growing smartphone penetration, and advancements in internet connectivity, will propel the demand for digital therapeutics in North America.

Some of the major players of digital therapeutics in the North America region are Proteus Digital Health, Inc., Omada Health, Inc., WellDoc, Inc., and Livongo Health, Inc., among others.

Thus, due to the interplay of all the above-mentioned factors, it will lead to an increase in North America digital therapeutics market growth during the forecast period from 2024 to 2030.

Digital Therapeutics Market key Players:

Some of the key market players operating in the Digital Therapeutics market include Limbix Health, Inc, GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc, Pear Therapeutics (US), Inc, CANARY HEALTH, Noom, Inc, Omada Health Inc, Welldoc, Inc, 2Morrow, Inc, ResMed, Teladoc Health, Inc, Fitbit Health Solutions, Huma, and others.

Recent Developmental Activities in the Digital Therapeutics Market:

• In January 2023, Lupin Digital Health, a wholly-owned subsidiary of global pharma major Lupin Limited, launched its digital therapeutics solution, LYFE. LYFE is India's only evidence-based holistic heart care program that significantly reduces the risk of a heart attack and improves vitals and quality of life for cardiac patients
• In June 2023, Huma, a leading global digital health company announced the U.S. Food and Drug Administration (FDA) Class II clearance for its disease-agnostic Software as a Medical Device (SaMD) platform.
• In May 2022, International digital therapeutics innovator, Sidekick Health, launched an integrated digital therapeutics solution for improving the outcomes of patients with Atopic Dermatitis (AD) in conjunction with Pfizer Inc.
• In April 2021, Mahana Therapeutics, Inc. received the US FDA 510(K) marketing clearance for its Mahana Parallel Digital Cognitive Behavioral Therapy (CBT) mobile application, which was substantially equivalent to a marketed predicate device for Irritable Bowel Syndrome (IBS).

Key Takeaways from the Digital Therapeutics Market Report Study

• Market size analysis for current Digital Therapeutics market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the digital therapeutics market
• Various opportunities available for the other competitors in the digital therapeutics market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current digital therapeutics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for digital therapeutics market growth in the coming future?

Target audience who can be benefited from this Digital Therapeutics Market Report Study

• Digital therapeutics products providers
• Research organizations and consulting companies
• Digital therapeutics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in digital therapeutics
• Various end-users who want to know more about the digital therapeutics market and the latest technological developments in the digital therapeutics market.

Frequently Asked Questions for the Digital Therapeutics Market:

1. What are digital therapeutics?

Digital Therapeutics (DTx) are evidence-based therapeutic interventions driven by software to prevent, manage, or treat a medical disorder or disease. In other words, DTx is a patient-facing software application that helps patients treat, prevent, or manage the disease and that has proven clinical benefits.

2. What is the market for digital therapeutics?

The digital therapeutics market is estimated to grow at a CAGR of 27.73% during the forecast period from 2024 to 2030.

3. What are the drivers for the digital therapeutics market?

The digital therapeutics market is slated to witness prosperity owing to the growing geriatric population prone to chronic diseases, the rising number of patients pool suffering from chronic diseases, the increasing usage of smartphones for digital therapeutics, the rising use of health monitoring apps, the cost-effectiveness of digital health technology for providers & patients, and increasing demand for integrated healthcare systems & patient-centric care among others, thereby contribute to the overall growth of the digital therapeutics market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the digital therapeutics market?

Some of the key market players operating in Digital Therapeutics include Limbix Health, Inc, GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc, Pear Therapeutics (US), Inc, CANARY HEALTH, Noom, Inc, Omada Health Inc, Welldoc, Inc, 2Morrow, Inc, ResMed, Teladoc Health, Inc, Fitbit Health Solutions, Huma, and others.

5. Which region has the highest share in the digital therapeutics market?

North America is expected to dominate the overall Digital Therapeutics market during the forecast period from 2024 to 2030. This is owing to the growing prevalence of chronic disorders such as diabetes, cardiovascular diseases, and cancers, among others, and the increasing geriatric population prone to chronic diseases will positively impact the North American digital therapeutics market. Furthermore, high disposable income, sophisticated healthcare infrastructure, incremental healthcare expenditure, an increasing number of start-ups, a well-developed healthcare sector, and increasing investments for R&D, among others also helped the market growth in this region.


This product will be delivered within 2 business days.